209 related articles for article (PubMed ID: 20145183)
1. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA; Waggoner S; von Gruenigen V; Eldermire E; Pink J; Dowlati A; Kinsella TJ
Clin Cancer Res; 2010 Feb; 16(4):1298-306. PubMed ID: 20145183
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Kunos CA; Radivoyevitch T; Waggoner S; Debernardo R; Zanotti K; Resnick K; Fusco N; Adams R; Redline R; Faulhaber P; Dowlati A
Gynecol Oncol; 2013 Jul; 130(1):75-80. PubMed ID: 23603372
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Kunos CA; Radivoyevitch T; Pink J; Chiu SM; Stefan T; Jacobberger J; Kinsella TJ
Radiat Res; 2010 Nov; 174(5):574-81. PubMed ID: 20954859
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
Martínez-Monge R; Gaztañaga M; Aramendía JM; Cambeiro M; Arbea L; Espinós J; Aristu JJ; Jurado M
Int J Gynecol Cancer; 2010 Jan; 20(1):133-40. PubMed ID: 20130514
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Mackenzie MJ; Saltman D; Hirte H; Low J; Johnson C; Pond G; Moore MJ
Invest New Drugs; 2007 Dec; 25(6):553-8. PubMed ID: 17585372
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.
Kunos CA; Colussi VC; Pink J; Radivoyevitch T; Oleinick NL
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1198-204. PubMed ID: 21470790
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
Mundt AJ; Rotmensch J; Waggoner SE; Yamada SD; Fleming GF
Gynecol Oncol; 2004 Mar; 92(3):801-5. PubMed ID: 14984944
[TBL] [Abstract][Full Text] [Related]
13. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
14. Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women.
Chumworathayi B; Yuenyao P; Tangvorapongchai V; Luanratanakorn S; Pattamadilok J; Krusun S
Radiat Med; 2007 Nov; 25(9):474-9. PubMed ID: 18026906
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.
Kunos CA; Radivoyevitch T; Ingalls ST; Hoppel CL
Future Oncol; 2012 Feb; 8(2):145-50. PubMed ID: 22335579
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Feun L; Modiano M; Lee K; Mao J; Marini A; Savaraj N; Plezia P; Almassian B; Colacino E; Fischer J; MacDonald S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):223-9. PubMed ID: 12203104
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.
DiSilvestro PA; Walker JL; Morrison A; Rose PG; Homesley H; Warshal D;
Gynecol Oncol; 2006 Dec; 103(3):1038-42. PubMed ID: 16889823
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer.
Martínez-Fernández MI; Legaspi Folgueira J; Valtueña Peydró G; Cambeiro M; Espinós J; Aramendía JM; Minguez-Milio JA; Martínez-Monge R
Int J Gynecol Cancer; 2016 Jul; 26(6):1162-8. PubMed ID: 27327153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
